REDWOOD CITY, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Deutsche Bank 40th Annual Health Care Conference on Thursday, May 7 at 1:30 pm ET in Boston.
A live and archived webcast of the presentation will be available on the Investor Relations page of the Coherus website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company with a focus on developing products for the major regulated markets. Composed of a team of industry veterans with decades of experience in bringing biologics to market, our goal is to become a worldwide leader in the biosimilar market by leveraging our biologics platform in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Coherus possesses late stage clinical products and commercialization partnerships with multinational pharmaceutical companies in Europe and Asia.
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com.
CONTACT: Susanna Chau Investor Relations Coherus BioSciences, Inc. firstname.lastname@example.org +1 (650) 649-3577